| Patent application number | Description | Published |
|---|
| 20090004192 | Recombinant anti-epidermal growth factor receptor antibody compositions - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody. | 01-01-2009 |
| 20100069262 | Method for Cloning Avian-Derived Antibodies - The invention relates to a procedure for linking cognate pairs of VH and VL encoding sequences from a population of avian cells enriched in particular surface antigen markers. The linking procedure involves a multiplex molecular amplification procedure capable of linking nucleotide sequences of interest in connection with the amplification (multiplex PCR). The method is particularly advantageous for the generation of cognate pair libraries as well as combinatorial libraries of antibody variable region encoding sequences from chickens or other birds. The invention also provides methods for generation of chimeric human/avian antibodies and expression libraries generated by such methods. | 03-18-2010 |
| 20110129855 | Recombinant Anti-Epidermal Growth Factor Receptor Antibody Compositions - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody. | 06-02-2011 |
| 20110135636 | Recombinant Anti-Epidermal Growth Factor Receptor Antibody Compositions - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody. | 06-09-2011 |
